-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Restrictions on some traditional Chinese medicines in the medical insurance catalogue are lifted, the pilot program of traditional Chinese medicine granules has ended, the centralized procurement of traditional Chinese medicines in Hubei has been moderately reduced, and the medical insurance supports the guiding opinions on the inheritance, innovation and development of traditional Chinese medicine.
.
.
In 2021, a series of heavy policies will be implemented one after another.
, the traditional Chinese medicine industry has been sought after by funds and has been well developed
.
Wind data shows that the Chinese Medicine Index has risen 9.
75% since December 22, 2021
.
In addition, the data shows that since December 1, 2021, three bull stocks have doubled in the traditional Chinese medicine sector: Longjin Pharmaceutical, Longshen Rongfa, and Essence Pharmaceutical
.
Among them, Longjin Pharmaceutical’s cumulative increase is huge, as high as 196%.
The data also shows that since December 22, Longjin Pharmaceutical has 12 daily daily limits in 15 trading days, with a cumulative increase of 190.
84%
.
According to the data, Longjin Pharmaceutical is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs
.
In order to change the single product structure and improve the overall anti-risk ability, in recent years, on the one hand, Longjin Pharmaceutical has continued to increase the R&D investment of chemical generic drugs and established projects to develop characteristic generic drugs to expand the product lifeline; Domestic and foreign R&D teams with mature technologies cooperate to build multiple platforms, diversify R&D risks, and improve R&D efficiency
.
It is reported that in the past three years, Longjin Pharmaceutical's R&D investment has accounted for an average of 10% of its sales revenue, and the proportion of R&D personnel to the total number of employees has exceeded 15% on average in three years
.
The data shows that the benefit of the core product breviscapine for injection is included in the double benefits of centralized procurement and the popularity of the traditional Chinese medicine sector.
Longjin Pharmaceutical has risen sharply from December 22 to 31, 2021, with 8 consecutive receipts.
daily limit
.
It is reported that the sales revenue of this product accounts for about 26.
54% of the company's operating revenue in the first three quarters of 2021 (about 99.
40% after deducting the income from pharmaceutical wholesale business), accounting for about 87.
74% of the company's operating revenue in 2020
.
Long Shenrong has posted a cumulative increase of 126% since December 1, 2021
.
It is understood that the main business of Longshen Rongfa is the production and sales of Chinese patent medicines, health foods and APIs, as well as pharmaceutical distribution business.
Currently, there are 4 dosage forms of drop pills, tablets, hard capsules, and films, and 16 medicines.
Production approval number and 1 health food approval number
.
In response to investors' questions, Longshen Rongfa stated that in the future development, the company will follow the overall strategic goal of Gansu Pharmaceutical Group to build a Longyao specialized industrial group, relying on the platform of listed companies to integrate high-quality assets in the industry, with large circulation, large The production platform is built as the core, and the company is built into a group company to revitalize the Longyao industry
.
Essence Pharma has risen 104% since December 1, 2021
.
According to the data, Essence Pharmaceutical is mainly an enterprise that develops, produces and sells medicines, and provides certain medicines for pharmaceutical companies
.
In recent years, Essence Pharma has continuously promoted product research and development and technological innovation, which has given the company a certain competitive advantage in the pharmaceutical industry.
At the same time, the company has also continued to do a good job in compliance management and strengthen internal management, which has played a positive role in the company's long-term development.
promotion
.
However, on January 4, 2022, Essence Pharmaceutical stated that it had received the "Reduction Plan" disclosed by Zhou Yunzhong, the company's director and general manager.
At present, it holds 3,865,500 shares of the company, with a shareholding ratio of 0.
46%, which is disclosed in this announcement.
After 15 trading days from today to July 25, 2022, the total reduction of the company's shares through centralized bidding transactions will not exceed 966,000 shares, accounting for 0.
12%
.
.
.
In 2021, a series of heavy policies will be implemented one after another.
, the traditional Chinese medicine industry has been sought after by funds and has been well developed
.
Wind data shows that the Chinese Medicine Index has risen 9.
75% since December 22, 2021
.
In addition, the data shows that since December 1, 2021, three bull stocks have doubled in the traditional Chinese medicine sector: Longjin Pharmaceutical, Longshen Rongfa, and Essence Pharmaceutical
.
Among them, Longjin Pharmaceutical’s cumulative increase is huge, as high as 196%.
The data also shows that since December 22, Longjin Pharmaceutical has 12 daily daily limits in 15 trading days, with a cumulative increase of 190.
84%
.
According to the data, Longjin Pharmaceutical is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs
.
In order to change the single product structure and improve the overall anti-risk ability, in recent years, on the one hand, Longjin Pharmaceutical has continued to increase the R&D investment of chemical generic drugs and established projects to develop characteristic generic drugs to expand the product lifeline; Domestic and foreign R&D teams with mature technologies cooperate to build multiple platforms, diversify R&D risks, and improve R&D efficiency
.
It is reported that in the past three years, Longjin Pharmaceutical's R&D investment has accounted for an average of 10% of its sales revenue, and the proportion of R&D personnel to the total number of employees has exceeded 15% on average in three years
.
The data shows that the benefit of the core product breviscapine for injection is included in the double benefits of centralized procurement and the popularity of the traditional Chinese medicine sector.
Longjin Pharmaceutical has risen sharply from December 22 to 31, 2021, with 8 consecutive receipts.
daily limit
.
It is reported that the sales revenue of this product accounts for about 26.
54% of the company's operating revenue in the first three quarters of 2021 (about 99.
40% after deducting the income from pharmaceutical wholesale business), accounting for about 87.
74% of the company's operating revenue in 2020
.
Long Shenrong has posted a cumulative increase of 126% since December 1, 2021
.
It is understood that the main business of Longshen Rongfa is the production and sales of Chinese patent medicines, health foods and APIs, as well as pharmaceutical distribution business.
Currently, there are 4 dosage forms of drop pills, tablets, hard capsules, and films, and 16 medicines.
Production approval number and 1 health food approval number
.
In response to investors' questions, Longshen Rongfa stated that in the future development, the company will follow the overall strategic goal of Gansu Pharmaceutical Group to build a Longyao specialized industrial group, relying on the platform of listed companies to integrate high-quality assets in the industry, with large circulation, large The production platform is built as the core, and the company is built into a group company to revitalize the Longyao industry
.
Essence Pharma has risen 104% since December 1, 2021
.
According to the data, Essence Pharmaceutical is mainly an enterprise that develops, produces and sells medicines, and provides certain medicines for pharmaceutical companies
.
In recent years, Essence Pharma has continuously promoted product research and development and technological innovation, which has given the company a certain competitive advantage in the pharmaceutical industry.
At the same time, the company has also continued to do a good job in compliance management and strengthen internal management, which has played a positive role in the company's long-term development.
promotion
.
However, on January 4, 2022, Essence Pharmaceutical stated that it had received the "Reduction Plan" disclosed by Zhou Yunzhong, the company's director and general manager.
At present, it holds 3,865,500 shares of the company, with a shareholding ratio of 0.
46%, which is disclosed in this announcement.
After 15 trading days from today to July 25, 2022, the total reduction of the company's shares through centralized bidding transactions will not exceed 966,000 shares, accounting for 0.
12%
.
